Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleDrug Discovery and Translational Medicine

Antibody-Conjugated, DNA-Based Nanocarriers Intercalated with Doxorubicin Eliminate Myofibroblasts in Explants of Human Lens Tissue

Jacquelyn Gerhart, Marvin Greenbaum, Lou Casta, Anthony Clemente, Keith Mathers, Robert Getts and Mindy George-Weinstein
Journal of Pharmacology and Experimental Therapeutics April 2017, 361 (1) 60-67; DOI: https://doi.org/10.1124/jpet.116.239079
Jacquelyn Gerhart
Genisphere, LLC, Hatfield, Pennsylvania (J.G., L.C., A.C., R.G.); Lankenau Medical Center, Wynnewood, Pennsylvania (M.G., K.M.); Cooper Medical School of Rowan University, Camden, New Jersey (M.G.-W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marvin Greenbaum
Genisphere, LLC, Hatfield, Pennsylvania (J.G., L.C., A.C., R.G.); Lankenau Medical Center, Wynnewood, Pennsylvania (M.G., K.M.); Cooper Medical School of Rowan University, Camden, New Jersey (M.G.-W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lou Casta
Genisphere, LLC, Hatfield, Pennsylvania (J.G., L.C., A.C., R.G.); Lankenau Medical Center, Wynnewood, Pennsylvania (M.G., K.M.); Cooper Medical School of Rowan University, Camden, New Jersey (M.G.-W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Clemente
Genisphere, LLC, Hatfield, Pennsylvania (J.G., L.C., A.C., R.G.); Lankenau Medical Center, Wynnewood, Pennsylvania (M.G., K.M.); Cooper Medical School of Rowan University, Camden, New Jersey (M.G.-W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith Mathers
Genisphere, LLC, Hatfield, Pennsylvania (J.G., L.C., A.C., R.G.); Lankenau Medical Center, Wynnewood, Pennsylvania (M.G., K.M.); Cooper Medical School of Rowan University, Camden, New Jersey (M.G.-W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Getts
Genisphere, LLC, Hatfield, Pennsylvania (J.G., L.C., A.C., R.G.); Lankenau Medical Center, Wynnewood, Pennsylvania (M.G., K.M.); Cooper Medical School of Rowan University, Camden, New Jersey (M.G.-W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mindy George-Weinstein
Genisphere, LLC, Hatfield, Pennsylvania (J.G., L.C., A.C., R.G.); Lankenau Medical Center, Wynnewood, Pennsylvania (M.G., K.M.); Cooper Medical School of Rowan University, Camden, New Jersey (M.G.-W.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Structure and internalization of G8:3DNA. (A) Schematic representation of the G8 IgM mAb coupled to a two-layer 3DNA nanocarrier intercalated with doxorubicin. (B) Proposed mechanism of targeted cytotoxicity in which doxorubicin diffuses from 3DNA following antibody binding and internalization of the conjugate into acidic compartments of the cell. (C–E) Anterior lens tissue was incubated for 2 hours with G8:3DNA:Cy3 (red) and LysoSensor dye that fluoresces green at acidic pH (C–E) or 3DNA:Cy3 and LysoSensor dye (F–H). Nuclei were labeled with Hoechst dye (blue). Colocalization of red and green (arrows in C and D) appears yellow in the merged image in E. Minimal incorporation of the nontargeting 3DNA:Cy3 conjugate was visible in the tissue (arrows in F-H). Bar, 9 μm in F-H, 5.67 in C and D, and 2.25 μm in E.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    G8:3DNA:Dox kills Myo/Nog cells in human lens tissue. Anterior human lens tissue was incubated with G8:3DNA (A–C), 3DNA:Dox (D­–F), or G8:3DNA:Dox (G–I) for 24 hours, beginning on the second day in culture. Lenses were fixed and labeled with antibodies to G8, α-SMA, or αB-crystalline and fluorescent secondary antibodies (green) and TUNEL reagents (red). Nuclei were stained with Hoechst dye (blue). Cells labeled with α-SMA also were targeted with G8:3DNA:Dox (J-L). Lens epithelial cells labeled with αB-crystalline were unaffected by G8:3DNA:Dox (M-O). Bar, 9 μm. Overlap of red and green appears yellow in merged images. G8:3DNA:Dox (G–I), but not the control conjugates (A–F), specifically killed Myo/Nog cells in lens explants. Bar, 9 μm.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Expression of Myo/Nog and muscle cell markers in long-term cultures of human lens tissue. Anterior lens tissue was cultured for 30 days and labeled with antibodies to G8, noggin, MyoD, sarcomeric myosin, α-SMA, and fluorescent secondary antibodies. Nuclei were stained with Hoechst dye (blue). Overlap of red and green appears yellow in merged images. G8+ cells contained noggin (A–C), MyoD (D–F), sarcomeric myosin (G–I), and α-SMA (J–L). Bar, 9 μm.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Effect of G8:3DNA:Dox on myofibroblast accumulation in long-term cultures of human lens tissue challenged by wounding. Anterior lens tissue was incubated with DMEM/F12 medium alone or medium containing 3DNA:Dox or G8:3DNA:DOX for 24 hours on day 1 only or days 1 and 13. The tissue was wounded on day 29 and stained for G8, fluorescent secondary antibodies (red), and α-SMA (green), or G8 and αB-crystalline the following day. Nuclei were stained with Hoechst dye (blue). Overlap of red and green appears yellow in merged images. G8+/α-SMA+ cells were present around the wound in cultures lacking drug (A–C) and those treated with 3DNA:Dox (G–I). Myo/Nog cells extended processes onto the capsule (I). G8+/α-SMA+ cells were rare in cultures treated with a single dose of G8:3DNA:Dox (n = 4) (D–F). Two doses of G8:3DNA:Dox completely eliminated G8+/α-SMA+ cells (J–L). Lens epithelial cells stained for αB-crystalline were unaffected by two doses of G8:3DNA:Dox [inset in (L)]. Bar, 9 μm.

Tables

  • Figures
    • View popup
    TABLE 1 

    Depletion of Myo/Nog cells with G8:3DNA:Dox in human lens cultures

    Anterior human lens explants were incubated with medium alone (untreated), G8:3DNA, 3DNA:Dox, or G8:3DNA:Dox for 24 hours. Cells were double-labeled with the G8 mAb and fluorescent secondary antibodies, and TUNEL reagents. The results are the mean ± standard deviation. Untreated, G8:3DNA and 3DNA:Dox, n = 5; G8:3DNA:Dox: n = 8. Significant differences were found between the percentages of TUNEL+ cells in all three control groups compared with G8:3DNA:Dox (P < 0.0001), untreated and 3DNA:Dox (P = 0.0005), and G8:3DNA and 3DNA:Dox (P = 0.02). % G8+ or TUNEL+ = (number of fluorescent cells ÷ total number of cells in 20 fields) × 100. % G8+ with TUNEL = (number of G8+ cells colabeled with the second primary antibody ÷ total G8+ cells) × 100. Reciprocal pairs are also presented. G8:3DNA:Dox, but not control conjugates, specifically killed G8+ cells.

    Treatment% G8+% TUNEL+% G8+ with TUNEL% TUNEL+ with G8
    Untreated4 ± 10.7 ± 0.200
    G8:3DNA4 ± 10.5 ± 0.300
    3DNA:Dox4 ± 20.1 ± 0.100
    G8:3DNA:Dox5 ± 15 ± 199 ± 299 ± 2
    • View popup
    TABLE 2 

    Expression of Myo/Nog and muscle cell markers in 30-day human lens cultures

    Anterior human lens explants were cultured for 30 days and doubled-labeled with antibodies to G8 and noggin, MyoD, α-SMA, and sarcomeric myosin and fluorescent secondary antibodies. The results are the mean ± standard deviation. The number of subject is indicated in parentheses.

    MarkersPercent Positive
    G86 ± 4 (18)
    Noggin5 ± 3 (7)
    MyoD1 ± 2 (4)
    Myosin4 ± 3 (4)
    α-SMA9 ± 5 (9)
    G8+ cells with Noggin100 (4)
    Noggin+ cells with G899 ± 3 (4)
    G8+ cells with MyoD24 ± 24 (4)
    MyoD+ cells with G8100 (4)
    G8+ with myosin53 ± 29 (4)
    Myosin+ cells with G8100 (4)
    G8+ cells with α-SMA 82 ± 22 (6)
    α-SMA+ cells with G867 ± 32 (6)
    • % positive = (number of fluorescent cells ÷ total number of cells in 20 fields) × 100. % G8+ with second primary antibody = (number of G8+ cells co-labeled with the second primary antibody ÷ total G8+ cells) × 100. Reciprocal pairs are also presented. All G8+ cells contained Noggin. Subpopulations of Myo/Nog cells contain different muscle proteins.

    • View popup
    TABLE 3 

    Effects of G8:3DNA:Dox on the accumulation of G8+ and α-SMA+ cells in 30-day, wounded human lens explants

    Anterior human lens explants were incubated with medium alone, 3DNA:Dox or G8:3DNA:Dox for 24 hours on the second and thirteenth day in culture. Wounds were created in the epithelium on day 29. Cells were double-labeled with antibodies to G8, fluorescent secondary antibodies, and α-SMA on day 30. The results are the mean ± standard deviation. The number of cultures is indicated in parentheses.

    Marker% Positive No drug% Positive G8:3DNA% Positive 3DNA:Dox% Positive G8:3DNA:Dox
    G89 ± 2 (4)9 ± 1 (4)8 ± 4 (n = 8)***0 (n = 7)
    α-SMA9 ± 2 (4)10 ± 1 (4)7 ± 3 (n = 6)***0 (n = 7)
    • % Positive = (number of fluorescent cells ÷ total number of cells in 20 fields) × 100. The number of cultures scored is indicated in parentheses. Two doses of G8:3DNA:Dox completely eliminated G8+/α-SMA+ cells in long-term lens cultures.

    • ↵*** P < 0.0001.

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 361 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 361, Issue 1
1 Apr 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Antibody-Conjugated, DNA-Based Nanocarriers Intercalated with Doxorubicin Eliminate Myofibroblasts in Explants of Human Lens Tissue
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleDrug Discovery and Translational Medicine

Immunodepletion of Lens Myofibroblasts with Cytotoxic 3DNA

Jacquelyn Gerhart, Marvin Greenbaum, Lou Casta, Anthony Clemente, Keith Mathers, Robert Getts and Mindy George-Weinstein
Journal of Pharmacology and Experimental Therapeutics April 1, 2017, 361 (1) 60-67; DOI: https://doi.org/10.1124/jpet.116.239079

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleDrug Discovery and Translational Medicine

Immunodepletion of Lens Myofibroblasts with Cytotoxic 3DNA

Jacquelyn Gerhart, Marvin Greenbaum, Lou Casta, Anthony Clemente, Keith Mathers, Robert Getts and Mindy George-Weinstein
Journal of Pharmacology and Experimental Therapeutics April 1, 2017, 361 (1) 60-67; DOI: https://doi.org/10.1124/jpet.116.239079
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Glucose transport modulators and mouse behavioral testing
  • Translational PK/PD Modeling of M3258
  • Kidney protective effects of BI 685509
Show more Drug Discovery and Translational Medicine

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics